Skip to content
Blerp – Lifestyle
Author:
VANDA PHARMACEUTICALS INC
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 5, 2026
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026
July 29, 2026
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis – A Milestone Recognition of GPP as a Distinct Rare Disease in Europe
July 16, 2026
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
July 15, 2026
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
July 10, 2026
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
July 7, 2026
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
May 27, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
May 8, 2026
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
May 7, 2026
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
May 6, 2026
1
2
Next Page
→